One in every nine seniors is living with Alzheimer’s disease, and the race to cure it is worth big money. While the FDA has approved some Alzheimer’s disease drugs, these can only slow the progression, not halt or reverse it.
Despite lacking efficacy, Alzheimer’s disease drugs currently charge exorbitant amounts because, for sufferers, there is no other choice. Since drugs are expensive and non-curative, the market is crying out for new drugs and ideas.
Betting on clinical trials is risky since the stock can swing wildly depending on the outcome. But if you are confident in the science and the hypothesis, it can pay off big time. All the companies mentioned here will have trials ending in 2023, giving time for a smart investor to get in before the hype.
This post appeared first on InvestorPlace.